Related Experiment Video
Updated: Jan 17, 2026
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Sunvozertinib Monotherapy in Advanced Lung Adenocarcinoma with EGFR Exon 20 Insertion and High PD-L1 Expression: A
1Department of Oncology, Liaocheng People's Hospital, Liaocheng City, Shandong Province, 252000, People's Republic of China.
Abstract:
As a key oncogenic driver in non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for 2-5% of EGFR-mutated NSCLC cases and display marked heterogeneity. Conventional EGFR tyrosine kinase inhibitors (TKIs) are ineffective against these mutations. Sunvozertinib, an orally administered, potent, and highly selective EGFR-TKI, has been approved in China for second-line treatment of NSCLC harboring EGFR exon 20 insertion mutations. Historically, patients with EGFR exon 20 insertion and high programmed death-ligand 1 (PD-L1) expression often received combined immunotherapy and chemotherapy. In the present case report, we describe a patient who exhibited intolerance to first-line immunochemotherapy and was subsequently switched to sunvozertinib for maintenance therapy. This regimen yielded a prolonged progression-free survival, with manageable safety and tolerability profiles. These findings demonstrated that sunvozertinib could be a promising first-line treatment option for NSCLC patients with EGFR exon 20 insertion.
Insights
Sunvozertinib shows promise as a first-line treatment for non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions. This targeted therapy offers prolonged progression-free survival and manageable safety in patients intolerant to initial treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) exon 20 insertion mutations are key drivers in non-small-cell lung cancer (NSCLC), affecting 2-5% of EGFR-mutated cases.
- These mutations confer resistance to conventional EGFR tyrosine kinase inhibitors (TKIs).
- Sunvozertinib is an approved EGFR-TKI in China for second-line treatment of NSCLC with EGFR exon 20 insertion mutations.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...